|Awarded On||August 20, 2014|
|Title||DNA Methylation and Telomere Length in Peripheral Blood as Predictors of Aggressive Prostate Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jian Gu|
The overall 5-year survival rate of prostate cancer patients is nearly 100%. However, accompanying the excellent prognosis is overtreatment in many patients, as the majority of screening-detected PCa are localized, slow growing, and pose little or no threat to the health or longevity of the patients. Most patients die of diseases other than PCa, yet about 90% of men with localized PCa receive upfront treatment with prostatectomy or radiotherapy that often causes significant morbidity, including urinary dysfunction, rectal bleeding, and impotence. Clinical parameters are not sufficient to accurately distinguish men who can be spared initial therapy from those needing aggressive therapy, resul...